Share Price and Basic Stock Data
Last Updated: January 22, 2026, 7:35 am
| PEG Ratio | 0.04 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Nath Bio-Genes (India) Ltd operates in the seeds, tissue culture, and biotechnology sector, which is crucial for agricultural advancements. The company’s stock price stood at ₹141, with a market capitalization of ₹265 Cr. Over the past financial year, the company’s sales demonstrated a significant upward trajectory, rising from ₹234 Cr in March 2023 to ₹265 Cr in March 2025. The trailing twelve months (TTM) sales reached ₹406 Cr, indicating robust growth. Quarterly sales peaked in June 2023 at ₹235.28 Cr, showcasing a strong seasonal demand. However, sales have shown fluctuations, with a notable decline to ₹22.57 Cr in September 2023, suggesting potential volatility in demand. The overall trend, however, indicates a positive growth trajectory in the medium term, supported by increasing agricultural biotechnology adoption and the company’s product offerings.
Profitability and Efficiency Metrics
Nath Bio-Genes reported a net profit of ₹50 Cr, translating to a price-to-earnings (P/E) ratio of 5.62, which is relatively low compared to sector standards, indicating potential undervaluation. The return on equity (ROE) stood at 6.77%, while the return on capital employed (ROCE) was reported at 7.35%, demonstrating efficient capital utilization. Operating profit margins (OPM) averaged 18.08%, with a peak of 37.02% in June 2023, reflecting the company’s ability to manage costs effectively during peak sales periods. However, the OPM dipped significantly in March 2025 to 6.42%, raising concerns regarding cost management in less favorable conditions. The interest coverage ratio (ICR) of 5.18x indicates a comfortable buffer for interest payments, though the cash conversion cycle (CCC) of 122 days suggests potential inefficiencies in inventory and receivables management that could be optimized.
Balance Sheet Strength and Financial Ratios
The balance sheet of Nath Bio-Genes reflects a solid foundation, with total assets reported at ₹1,005 Cr and total liabilities at ₹1,017 Cr, highlighting a manageable debt level with total borrowings of ₹142 Cr. The company holds reserves of ₹668 Cr, which provides a cushion for future investments and operational stability. The debt-to-equity ratio is relatively low at 0.19x, indicating prudent leverage practices. The book value per share stood at ₹339.08, significantly higher than the current market price, suggesting that the stock may be undervalued. The current ratio of 1.89x indicates adequate liquidity to cover short-term obligations. However, the efficiency metrics, such as the cash conversion cycle and inventory turnover ratio of 1.28x, suggest areas for improvement in operational efficiency and working capital management.
Shareholding Pattern and Investor Confidence
Nath Bio-Genes has a stable shareholding structure, with promoters holding 45.59% of the equity, which indicates strong management commitment. The public holds 53.31%, reflecting broad-based investor interest, although foreign institutional investors (FIIs) account for only 0.32%, suggesting limited international confidence in the stock. Domestic institutional investors (DIIs) hold a modest 0.76%, indicating potential for increased institutional interest. The number of shareholders stood at 34,122, which indicates a growing retail investor base. The recent trend shows an increase in public shareholding from 49.62% in December 2022 to 53.31% in September 2025, reflecting rising investor confidence. However, the low FII and DII participation could pose risks, as institutional backing often enhances stock stability and credibility in the market.
Outlook, Risks, and Final Insight
The outlook for Nath Bio-Genes appears cautiously optimistic, driven by increasing demand in the agricultural biotechnology sector and a solid revenue growth trajectory. However, risks include potential volatility in sales, as evidenced by the fluctuations in quarterly performance, and challenges in managing operational efficiencies, particularly in inventory and receivables. Furthermore, low institutional participation may hinder stock price appreciation. Strengths lie in the company’s robust reserves, low debt levels, and strong promoter backing, which provide stability and growth potential. In scenarios where the company can enhance operational efficiencies and attract more institutional investors, it may experience improved valuations and market confidence. Conversely, failure to address sales volatility and efficiency issues may lead to continued market skepticism and price pressures.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Genomic Valley Biotech Ltd | 6.99 Cr. | 22.9 | 70.9/21.0 | 12.8 | 0.00 % | 11.8 % | 9.69 % | 10.0 | |
| Genesis IBRC India Ltd | 94.9 Cr. | 73.0 | 185/18.3 | 6.42 | 0.00 % | 51.6 % | 51.6 % | 10.0 | |
| Shreeoswal Seeds & Chemicals Ltd | 125 Cr. | 13.7 | 20.3/10.7 | 12.5 | 5.23 | 0.00 % | 9.88 % | 8.41 % | 2.00 |
| Nath Bio-Genes (India) Ltd | 267 Cr. | 141 | 239/136 | 5.67 | 362 | 1.42 % | 7.35 % | 6.77 % | 10.0 |
| Continental Seeds and Chemicals Ltd | 28.8 Cr. | 21.0 | 34.8/19.3 | 37.4 | 22.5 | 0.00 % | 4.24 % | 2.87 % | 10.0 |
| Industry Average | 196.00 Cr | 54.32 | 18.52 | 81.79 | 0.28% | 16.97% | 15.87% | 8.40 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.73 | 25.30 | 44.92 | 235.28 | 22.57 | 31.74 | 43.04 | 243.88 | 32.19 | 36.87 | 49.37 | 280.17 | 39.77 |
| Expenses | 16.98 | 19.68 | 40.84 | 198.26 | 17.48 | 25.96 | 38.57 | 206.82 | 25.63 | 29.36 | 46.20 | 241.27 | 32.58 |
| Operating Profit | 4.75 | 5.62 | 4.08 | 37.02 | 5.09 | 5.78 | 4.47 | 37.06 | 6.56 | 7.51 | 3.17 | 38.90 | 7.19 |
| OPM % | 21.86% | 22.21% | 9.08% | 15.73% | 22.55% | 18.21% | 10.39% | 15.20% | 20.38% | 20.37% | 6.42% | 13.88% | 18.08% |
| Other Income | 0.20 | 0.06 | 0.26 | 0.12 | 0.06 | 2.54 | 1.39 | 0.14 | 0.07 | 0.48 | 4.58 | 3.83 | 1.93 |
| Interest | 2.75 | 2.96 | 1.53 | 2.76 | 2.44 | 2.84 | 1.06 | 2.24 | 2.94 | 3.37 | 1.10 | 2.89 | 3.30 |
| Depreciation | 0.67 | 0.67 | 0.99 | 0.76 | 0.76 | 0.76 | 0.98 | 0.83 | 0.83 | 0.83 | 1.32 | 0.98 | 0.98 |
| Profit before tax | 1.53 | 2.05 | 1.82 | 33.62 | 1.95 | 4.72 | 3.82 | 34.13 | 2.86 | 3.79 | 5.33 | 38.86 | 4.84 |
| Tax % | 3.92% | 34.15% | 12.64% | 0.65% | 17.95% | 16.31% | 16.23% | 0.73% | -1.05% | 30.08% | 11.82% | 1.70% | 13.22% |
| Net Profit | 1.47 | 1.35 | 1.59 | 33.40 | 1.61 | 3.96 | 3.21 | 33.89 | 2.89 | 2.66 | 4.71 | 38.21 | 4.20 |
| EPS in Rs | 0.77 | 0.71 | 0.84 | 17.58 | 0.85 | 2.08 | 1.69 | 17.83 | 1.52 | 1.40 | 2.48 | 20.11 | 2.21 |
Last Updated: January 11, 2026, 7:47 am
Below is a detailed analysis of the quarterly data for Nath Bio-Genes (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 39.77 Cr.. The value appears to be declining and may need further review. It has decreased from 280.17 Cr. (Jun 2025) to 39.77 Cr., marking a decrease of 240.40 Cr..
- For Expenses, as of Sep 2025, the value is 32.58 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 241.27 Cr. (Jun 2025) to 32.58 Cr., marking a decrease of 208.69 Cr..
- For Operating Profit, as of Sep 2025, the value is 7.19 Cr.. The value appears to be declining and may need further review. It has decreased from 38.90 Cr. (Jun 2025) to 7.19 Cr., marking a decrease of 31.71 Cr..
- For OPM %, as of Sep 2025, the value is 18.08%. The value appears strong and on an upward trend. It has increased from 13.88% (Jun 2025) to 18.08%, marking an increase of 4.20%.
- For Other Income, as of Sep 2025, the value is 1.93 Cr.. The value appears to be declining and may need further review. It has decreased from 3.83 Cr. (Jun 2025) to 1.93 Cr., marking a decrease of 1.90 Cr..
- For Interest, as of Sep 2025, the value is 3.30 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.89 Cr. (Jun 2025) to 3.30 Cr., marking an increase of 0.41 Cr..
- For Depreciation, as of Sep 2025, the value is 0.98 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.98 Cr..
- For Profit before tax, as of Sep 2025, the value is 4.84 Cr.. The value appears to be declining and may need further review. It has decreased from 38.86 Cr. (Jun 2025) to 4.84 Cr., marking a decrease of 34.02 Cr..
- For Tax %, as of Sep 2025, the value is 13.22%. The value appears to be increasing, which may not be favorable. It has increased from 1.70% (Jun 2025) to 13.22%, marking an increase of 11.52%.
- For Net Profit, as of Sep 2025, the value is 4.20 Cr.. The value appears to be declining and may need further review. It has decreased from 38.21 Cr. (Jun 2025) to 4.20 Cr., marking a decrease of 34.01 Cr..
- For EPS in Rs, as of Sep 2025, the value is 2.21. The value appears to be declining and may need further review. It has decreased from 20.11 (Jun 2025) to 2.21, marking a decrease of 17.90.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:55 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 136 | 143 | 127 | 142 | 171 | 206 | 246 | 271 | 230 | 234 | 248 | 265 | 406 |
| Expenses | 102 | 109 | 103 | 113 | 131 | 163 | 191 | 204 | 193 | 185 | 197 | 212 | 349 |
| Operating Profit | 34 | 35 | 25 | 29 | 40 | 43 | 55 | 67 | 37 | 49 | 50 | 53 | 57 |
| OPM % | 25% | 24% | 19% | 20% | 24% | 21% | 22% | 25% | 16% | 21% | 20% | 20% | 14% |
| Other Income | 1 | 1 | 1 | 0 | 1 | 2 | 2 | 2 | -87 | 1 | 4 | 4 | 11 |
| Interest | 4 | 5 | 6 | 10 | 10 | 5 | 7 | 9 | 11 | 10 | 9 | 10 | 11 |
| Depreciation | 5 | 4 | 4 | 3 | 1 | 1 | 1 | 3 | 3 | 3 | 3 | 4 | 4 |
| Profit before tax | 26 | 26 | 15 | 17 | 30 | 39 | 49 | 57 | -63 | 36 | 42 | 44 | 53 |
| Tax % | 5% | 4% | 6% | 3% | 2% | 1% | -4% | 2% | 6% | 3% | 5% | 4% | |
| Net Profit | 24 | 25 | 14 | 16 | 29 | 38 | 50 | 56 | -67 | 35 | 40 | 42 | 50 |
| EPS in Rs | 15.18 | 15.87 | 8.85 | 10.17 | 15.48 | 20.22 | 26.56 | 29.29 | -35.43 | 18.51 | 21.14 | 22.17 | 26.20 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 7% | -6% | 11% | 9% | 9% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 4.17% | -44.00% | 14.29% | 81.25% | 31.03% | 31.58% | 12.00% | -219.64% | 152.24% | 14.29% | 5.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -48.17% | 58.29% | 66.96% | -50.22% | 0.54% | -19.58% | -231.64% | 371.88% | -137.95% | -9.29% |
Nath Bio-Genes (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 2% |
| 3 Years: | 5% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | -3% |
| 3 Years: | 21% |
| TTM: | 17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -10% |
| 3 Years: | -1% |
| 1 Year: | -22% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 7% |
| 3 Years: | 6% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 11:35 am
Balance Sheet
Last Updated: December 4, 2025, 1:42 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 19 | 19 | 19 | 19 | 19 | 19 | 19 | 19 | 19 |
| Reserves | 66 | 91 | 105 | 287 | 450 | 489 | 539 | 594 | 523 | 554 | 592 | 630 | 668 |
| Borrowings | 23 | 22 | 59 | 74 | 33 | 58 | 70 | 101 | 93 | 105 | 108 | 111 | 142 |
| Other Liabilities | 85 | 97 | 87 | 78 | 69 | 80 | 102 | 75 | 105 | 114 | 158 | 257 | 176 |
| Total Liabilities | 190 | 226 | 267 | 455 | 571 | 646 | 730 | 790 | 740 | 793 | 877 | 1,017 | 1,005 |
| Fixed Assets | 17 | 13 | 30 | 207 | 211 | 232 | 246 | 247 | 245 | 244 | 249 | 250 | 249 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 |
| Other Assets | 168 | 208 | 231 | 243 | 355 | 409 | 479 | 538 | 490 | 544 | 622 | 761 | 750 |
| Total Assets | 190 | 226 | 267 | 455 | 571 | 646 | 730 | 790 | 740 | 793 | 877 | 1,017 | 1,005 |
Below is a detailed analysis of the balance sheet data for Nath Bio-Genes (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 19.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 19.00 Cr..
- For Reserves, as of Sep 2025, the value is 668.00 Cr.. The value appears strong and on an upward trend. It has increased from 630.00 Cr. (Mar 2025) to 668.00 Cr., marking an increase of 38.00 Cr..
- For Borrowings, as of Sep 2025, the value is 142.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 111.00 Cr. (Mar 2025) to 142.00 Cr., marking an increase of 31.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 176.00 Cr.. The value appears to be improving (decreasing). It has decreased from 257.00 Cr. (Mar 2025) to 176.00 Cr., marking a decrease of 81.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,005.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,017.00 Cr. (Mar 2025) to 1,005.00 Cr., marking a decrease of 12.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 249.00 Cr.. The value appears to be declining and may need further review. It has decreased from 250.00 Cr. (Mar 2025) to 249.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
- For Other Assets, as of Sep 2025, the value is 750.00 Cr.. The value appears to be declining and may need further review. It has decreased from 761.00 Cr. (Mar 2025) to 750.00 Cr., marking a decrease of 11.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,005.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,017.00 Cr. (Mar 2025) to 1,005.00 Cr., marking a decrease of 12.00 Cr..
Notably, the Reserves (668.00 Cr.) exceed the Borrowings (142.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 11.00 | 13.00 | -34.00 | -45.00 | 7.00 | -15.00 | -15.00 | -34.00 | -56.00 | -56.00 | -58.00 | -58.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 95 | 114 | 130 | 133 | 175 | 191 | 159 | 147 | 136 | 152 | 139 | 122 |
| Inventory Days | 3,840 | 4,743 | 4,388 | |||||||||
| Days Payable | 1,309 | 1,406 | 586 | |||||||||
| Cash Conversion Cycle | 95 | 114 | 130 | 2,665 | 3,512 | 191 | 159 | 147 | 136 | 3,954 | 139 | 122 |
| Working Capital Days | 126 | 190 | 259 | 273 | 447 | 442 | 416 | 450 | 427 | 416 | 343 | 316 |
| ROCE % | 33% | 26% | 14% | 10% | 9% | 8% | 9% | 10% | 5% | 7% | 7% | 7% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Aditya Birla Sun Life Value Fund | 126,341 | 0.03 | 2.08 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 13 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 19.85 | 19.52 | 18.43 | -35.55 | 7.34 |
| Diluted EPS (Rs.) | 19.85 | 19.52 | 18.43 | -35.55 | 7.34 |
| Cash EPS (Rs.) | 22.32 | 22.56 | 20.01 | -33.84 | 10.16 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 339.08 | 320.94 | 301.60 | 285.16 | 35.91 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 339.08 | 320.94 | 301.60 | 285.16 | 35.91 |
| Revenue From Operations / Share (Rs.) | 192.02 | 175.03 | 158.58 | 146.47 | 86.04 |
| PBDIT / Share (Rs.) | 28.60 | 26.57 | 25.94 | 20.54 | 12.80 |
| PBIT / Share (Rs.) | 26.59 | 24.85 | 24.36 | 18.92 | 9.98 |
| PBT / Share (Rs.) | 21.36 | 21.87 | 19.03 | -33.38 | 7.68 |
| Net Profit / Share (Rs.) | 20.31 | 20.85 | 18.42 | -35.46 | 7.34 |
| NP After MI And SOA / Share (Rs.) | 20.31 | 20.85 | 18.42 | -35.46 | 7.34 |
| PBDIT Margin (%) | 14.89 | 15.17 | 16.35 | 14.02 | 14.87 |
| PBIT Margin (%) | 13.84 | 14.19 | 15.35 | 12.91 | 11.59 |
| PBT Margin (%) | 11.12 | 12.49 | 12.00 | -22.78 | 8.92 |
| Net Profit Margin (%) | 10.57 | 11.91 | 11.61 | -24.20 | 8.52 |
| NP After MI And SOA Margin (%) | 10.57 | 11.91 | 11.61 | -24.20 | 8.52 |
| Return on Networth / Equity (%) | 5.99 | 6.49 | 6.10 | -12.43 | 20.43 |
| Return on Capital Employeed (%) | 7.64 | 7.64 | 8.03 | 6.59 | 26.54 |
| Return On Assets (%) | 3.76 | 4.50 | 4.41 | -9.11 | 7.42 |
| Long Term Debt / Equity (X) | 0.02 | 0.01 | 0.00 | 0.00 | 0.02 |
| Total Debt / Equity (X) | 0.19 | 0.18 | 0.18 | 0.17 | 0.31 |
| Asset Turnover Ratio (%) | 0.38 | 0.39 | 0.39 | 0.00 | 1.05 |
| Current Ratio (X) | 1.89 | 2.18 | 2.41 | 2.41 | 1.22 |
| Quick Ratio (X) | 0.96 | 1.30 | 1.45 | 1.27 | 0.43 |
| Inventory Turnover Ratio (X) | 1.28 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 9.84 | 9.59 | 10.85 | -5.64 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 8.96 | 8.86 | 9.99 | -5.91 | 0.00 |
| Earning Retention Ratio (%) | 90.16 | 90.41 | 89.15 | 105.64 | 0.00 |
| Cash Earning Retention Ratio (%) | 91.04 | 91.14 | 90.01 | 105.91 | 0.00 |
| Interest Coverage Ratio (X) | 5.18 | 5.54 | 4.87 | 3.68 | 5.58 |
| Interest Coverage Ratio (Post Tax) (X) | 4.63 | 4.97 | 4.46 | 3.02 | 4.20 |
| Enterprise Value (Cr.) | 310.77 | 363.13 | 336.48 | 494.22 | 0.00 |
| EV / Net Operating Revenue (X) | 0.85 | 1.09 | 1.12 | 1.78 | 0.00 |
| EV / EBITDA (X) | 5.72 | 7.19 | 6.83 | 12.66 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.75 | 0.99 | 0.89 | 1.46 | 0.00 |
| Retention Ratios (%) | 90.15 | 90.40 | 89.14 | 105.64 | 0.00 |
| Price / BV (X) | 0.43 | 0.54 | 0.46 | 0.74 | 0.00 |
| Price / Net Operating Revenue (X) | 0.75 | 0.99 | 0.89 | 1.46 | 0.00 |
| EarningsYield | 0.13 | 0.11 | 0.13 | -0.16 | 0.00 |
After reviewing the key financial ratios for Nath Bio-Genes (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 19.85. This value is within the healthy range. It has increased from 19.52 (Mar 24) to 19.85, marking an increase of 0.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 19.85. This value is within the healthy range. It has increased from 19.52 (Mar 24) to 19.85, marking an increase of 0.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 22.32. This value is within the healthy range. It has decreased from 22.56 (Mar 24) to 22.32, marking a decrease of 0.24.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 339.08. It has increased from 320.94 (Mar 24) to 339.08, marking an increase of 18.14.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 339.08. It has increased from 320.94 (Mar 24) to 339.08, marking an increase of 18.14.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 192.02. It has increased from 175.03 (Mar 24) to 192.02, marking an increase of 16.99.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 28.60. This value is within the healthy range. It has increased from 26.57 (Mar 24) to 28.60, marking an increase of 2.03.
- For PBIT / Share (Rs.), as of Mar 25, the value is 26.59. This value is within the healthy range. It has increased from 24.85 (Mar 24) to 26.59, marking an increase of 1.74.
- For PBT / Share (Rs.), as of Mar 25, the value is 21.36. This value is within the healthy range. It has decreased from 21.87 (Mar 24) to 21.36, marking a decrease of 0.51.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 20.31. This value is within the healthy range. It has decreased from 20.85 (Mar 24) to 20.31, marking a decrease of 0.54.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 20.31. This value is within the healthy range. It has decreased from 20.85 (Mar 24) to 20.31, marking a decrease of 0.54.
- For PBDIT Margin (%), as of Mar 25, the value is 14.89. This value is within the healthy range. It has decreased from 15.17 (Mar 24) to 14.89, marking a decrease of 0.28.
- For PBIT Margin (%), as of Mar 25, the value is 13.84. This value is within the healthy range. It has decreased from 14.19 (Mar 24) to 13.84, marking a decrease of 0.35.
- For PBT Margin (%), as of Mar 25, the value is 11.12. This value is within the healthy range. It has decreased from 12.49 (Mar 24) to 11.12, marking a decrease of 1.37.
- For Net Profit Margin (%), as of Mar 25, the value is 10.57. This value exceeds the healthy maximum of 10. It has decreased from 11.91 (Mar 24) to 10.57, marking a decrease of 1.34.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.57. This value is within the healthy range. It has decreased from 11.91 (Mar 24) to 10.57, marking a decrease of 1.34.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.99. This value is below the healthy minimum of 15. It has decreased from 6.49 (Mar 24) to 5.99, marking a decrease of 0.50.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.64. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 7.64.
- For Return On Assets (%), as of Mar 25, the value is 3.76. This value is below the healthy minimum of 5. It has decreased from 4.50 (Mar 24) to 3.76, marking a decrease of 0.74.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. It has increased from 0.18 (Mar 24) to 0.19, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.38. It has decreased from 0.39 (Mar 24) to 0.38, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has decreased from 2.18 (Mar 24) to 1.89, marking a decrease of 0.29.
- For Quick Ratio (X), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 1. It has decreased from 1.30 (Mar 24) to 0.96, marking a decrease of 0.34.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.28. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 1.28, marking an increase of 1.28.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.84. This value is below the healthy minimum of 20. It has increased from 9.59 (Mar 24) to 9.84, marking an increase of 0.25.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.96. This value is below the healthy minimum of 20. It has increased from 8.86 (Mar 24) to 8.96, marking an increase of 0.10.
- For Earning Retention Ratio (%), as of Mar 25, the value is 90.16. This value exceeds the healthy maximum of 70. It has decreased from 90.41 (Mar 24) to 90.16, marking a decrease of 0.25.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.04. This value exceeds the healthy maximum of 70. It has decreased from 91.14 (Mar 24) to 91.04, marking a decrease of 0.10.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.18. This value is within the healthy range. It has decreased from 5.54 (Mar 24) to 5.18, marking a decrease of 0.36.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.63. This value is within the healthy range. It has decreased from 4.97 (Mar 24) to 4.63, marking a decrease of 0.34.
- For Enterprise Value (Cr.), as of Mar 25, the value is 310.77. It has decreased from 363.13 (Mar 24) to 310.77, marking a decrease of 52.36.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 1. It has decreased from 1.09 (Mar 24) to 0.85, marking a decrease of 0.24.
- For EV / EBITDA (X), as of Mar 25, the value is 5.72. This value is within the healthy range. It has decreased from 7.19 (Mar 24) to 5.72, marking a decrease of 1.47.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.75, marking a decrease of 0.24.
- For Retention Ratios (%), as of Mar 25, the value is 90.15. This value exceeds the healthy maximum of 70. It has decreased from 90.40 (Mar 24) to 90.15, marking a decrease of 0.25.
- For Price / BV (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has decreased from 0.54 (Mar 24) to 0.43, marking a decrease of 0.11.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.75, marking a decrease of 0.24.
- For EarningsYield, as of Mar 25, the value is 0.13. This value is below the healthy minimum of 5. It has increased from 0.11 (Mar 24) to 0.13, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Nath Bio-Genes (India) Ltd:
- Net Profit Margin: 10.57%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.64% (Industry Average ROCE: 16.97%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.99% (Industry Average ROE: 15.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.63
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.96
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 5.67 (Industry average Stock P/E: 18.52)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.57%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Seeds/Tissue Culture/Bio Technology | Nath House, Aurangabad Maharashtra 431005 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Satish Kagliwal | Managing Director |
| Mr. Madhukar Deshpande | Director |
| Ms. Ashu Jain | Director |
| Mrs. Jeevanlata Kagliwal | Director |
| Mr. Vadla Nagabhushanam | Director |
| Mr. Hitesh Purohit | Director |
| Mr. Akash Kagliwal | Director |
FAQ
What is the intrinsic value of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd's intrinsic value (as of 22 January 2026) is ₹257.89 which is 82.90% higher the current market price of ₹141.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹267 Cr. market cap, FY2025-2026 high/low of ₹239/136, reserves of ₹668 Cr, and liabilities of ₹1,005 Cr.
What is the Market Cap of Nath Bio-Genes (India) Ltd?
The Market Cap of Nath Bio-Genes (India) Ltd is 267 Cr..
What is the current Stock Price of Nath Bio-Genes (India) Ltd as on 22 January 2026?
The current stock price of Nath Bio-Genes (India) Ltd as on 22 January 2026 is ₹141.
What is the High / Low of Nath Bio-Genes (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Nath Bio-Genes (India) Ltd stocks is ₹239/136.
What is the Stock P/E of Nath Bio-Genes (India) Ltd?
The Stock P/E of Nath Bio-Genes (India) Ltd is 5.67.
What is the Book Value of Nath Bio-Genes (India) Ltd?
The Book Value of Nath Bio-Genes (India) Ltd is 362.
What is the Dividend Yield of Nath Bio-Genes (India) Ltd?
The Dividend Yield of Nath Bio-Genes (India) Ltd is 1.42 %.
What is the ROCE of Nath Bio-Genes (India) Ltd?
The ROCE of Nath Bio-Genes (India) Ltd is 7.35 %.
What is the ROE of Nath Bio-Genes (India) Ltd?
The ROE of Nath Bio-Genes (India) Ltd is 6.77 %.
What is the Face Value of Nath Bio-Genes (India) Ltd?
The Face Value of Nath Bio-Genes (India) Ltd is 10.0.